NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
PDG Explores $1 Billion Sale of China Data Center Assets 
Toshifumi Suzuki, Founder of Seven-Eleven Japan, Dies at 93 
Ferrari Luce: How Ferrari Evolved From Hybrid Supercars to Its First Fully Electric Vehicle 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
EU Antitrust Probe Could Lead to Massive Google Fine Under DMA Rules 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Celltrion just completed the phase 3 trial for its COVID-19 antibody treatment and it has shown very positive results. The biopharmaceutical company headquartered in Incheon, South Korea proves the efficacy of its treatment and full phase 3 results will follow before this month ends.
Outcome of phase 3 tests for the new COVID-19 antibody treatment
Celltrion said on Monday, June 14, that phase 3 of the clinical study for its Rekirona, yielded good results. This means that it was proven to be safe and effective after being tested with volunteer patients from 13 countries worldwide.
As per The Korea Herald, 1,315 patients took part in the third phase trial for Rekirona or CT-P59. The tests were conducted between the months of January and April of this year.
The South Korean biotech company stated that the treatment is effective and significantly reduced the recovery time and rate of progression for acute symptoms of COVID-19. Celltrion discovered through the phase 3 trial that the risk of cases progressing to a severe condition of coronavirus infection was reduced by 70%. In the high-risk group of patients, the progression rate to severe stage was said to have been cut by 72%.
What’s more, those treated with Celltrion’s Rekirona also showed significant results in recovery time as it was shortened. It was said that recovering from the disease was 4.7 to 4.9 days faster compared to others who used other treatments, Yonhap News Agency reported.
Most importantly, it was reported that the Celltrion COVID-19 antibody treatment did not show any serious adverse reaction. Only mild and temporary reactions were noted on the patients during the trial.
Celltrion’s shares surge after Celltrion’s phase 3 trial results were announced
Meanwhile, Pulse News reported that Celltrion’s shares increased by 5.08 percent to ₩279,000 or around $249.69 after the phase 3 test results for Rekirona were revealed. Celltrion Pharm, the company’s drug developing unit’s shares also went up by 12.54 percent to ₩156,200 while Celltrion Healthcare’s shares surged to 5.02 percent to ₩123,500.
In any case, Celltrion will now use the good results to seek marketing approval for the Covid-19 therapy in the U.S. The company will submit the documents to the U.S. Food and Drug Administration and the European Medicines Agency so it can be allowed to sell the treatment in the said regions.
